1-3 of 3
Brian West, Ph.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Catherine C Smith, MD, Kimberly Lin, BS, Elisabeth Lasater, PhD, Whitney Stewart, BS, Lauren E Damon, Andrew Kasarskis, PhD, Ali Bashir, PhD, Matthew Pendleton, Robert Sebra, Alexander E Perl, MD, Mai H Le, MD, Chao Zhang, PhD, Brian West, Ph.D., Neil P. Shah, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3938.
https://doi.org/10.1182/blood.V122.21.3938.3938
Published: 2013
Journal Articles

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

Craig H. Moskowitz, MD, Anas Younes, MD, Sven de Vos, MD, PhD, R. Gregory Bociek, MD, Leo I. Gordon, MD, Thomas E. Witzig, MD, Randy D. Gascoyne, MD, Brian West, Ph.D., Keith Nolop, MD, Christian Steidl, MD
Journal: Blood
Blood (2012) 120 (21): 1638.
https://doi.org/10.1182/blood.V120.21.1638.1638
Published: 2012
Journal Articles

The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,

Elizabeth Burton, Ph.D., Bernice Wong, Jiazhong Zhang, Ph.D., Brian West, Ph.D., Gideon Bollag, Ph.D., Gaston Habets, Ph.D., Allison Galanis, Hoa Nguyen, Omotayo Arowojolu, Trivikram Rajhowa, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3632.
https://doi.org/10.1182/blood.V118.21.3632.3632
Published: 2011